Fig. 3
From: Anti-Axl antibody treatment reduces the severity of experimental autoimmune encephalomyelitis
α-Axl antibody treatment has no effect on the number of Iba1+ microglia, T cells, Tregs, or axonal damage in the spinal cord during acute EAE. Quantification of Iba1 (a), CD3 (b), FoxP3 (c), and SMI32 (d) immune-stained lumbar spinal cord sections of PBS- (n = 6), IgG isotype control- (n = 6), or α-Axl-activating antibody-treated (n = 6) mice during acute EAE. Quantification of the SMI32+ axonal swellings (> 3 μm) was conducted on multiple × 20 fields of the left and the right ventral regions of the lumbar spinal cord. *p ≤ 0.05, Mann-Whitney U test